Infergen market forecast points to long-term growth despite shift in hepatitis C care

The Business Research Company says the Infergen market should keep expanding through 2035, driven by chronic hepatitis C cases, personalized medicine and healthcare investment. The report also points to North America as the largest market in 2025 and Asia-Pacific as the fastest-growing region.

Why it matters: - Infergen still has a market role in chronic hepatitis C, even as direct-acting antivirals take over most treatment use. - The forecast matters because the drug remains relevant in niche cases, including patients resistant to standard therapies and those needing closer liver-disease management. - The report links market demand to broader hepatitis screening, treatment access and long-term liver health outcomes.

What happened: - The Business Research Company released a Trends and Forecast Analysis of the Infergen Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the Infergen market is evolving as treatment approaches shift worldwide. - North America held the largest share of the Infergen market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company offers a free sample of the report and a full market report.

The details: - Infergen, also known as interferon alfacon-1, is a recombinant type-I interferon used mainly in adults with chronic hepatitis C and compensated liver disease. - Infergen is produced using genetically engineered Escherichia coli bacteria. - The therapy is designed to imitate interferons naturally present in the human body and stimulate the immune system against hepatitis C. - Historic market growth was supported by the prevalence of hepatitis C, the earlier reliance on interferon-based therapies, limited antiviral alternatives, hospital-based treatment protocols and clinician familiarity with interferons. - Future growth is expected to be shaped by the move toward direct-acting antivirals, demand in resistant cases, better hepatitis screening, stronger focus on liver disease management and declining dependence on interferon therapies. - Forecast trends include reduced use of interferon treatments, targeted use in resistant patients, optimization of combination therapies, efforts to suppress viral load and closer monitoring of long-term liver outcomes. - Chronic hepatitis C can persist for more than six months and can lead to liver damage, cirrhosis and liver cancer if untreated. - Rising injection drug use and limited access to prevention and treatment services are helping drive chronic hepatitis C cases. - The European Centre for Disease Prevention and Control reported 28,622 hepatitis C cases across 29 EU/EEA countries in 2023, with 34.1% classified as chronic. - Personalized medicine is another growth driver because treatment can be tailored to a patient’s genetic makeup, lifestyle and health conditions. - Infergen can be customized based on factors such as viral load and hepatitis C genotype. - In 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for rare diseases, up from the previous year. - Expanding healthcare infrastructure is also supporting the market by improving access to diagnostics, monitoring and side-effect management. - UK healthcare spending reached about US$414 billion in 2024, up 6.5% from the prior year.

Between the lines: - The market outlook shows a therapy in transition: Infergen is losing broad relevance but may retain value where newer options do not fully solve the clinical problem. - The strongest demand signals are coming from regions and care settings with improving diagnosis, treatment access and chronic liver disease management. - Personalized medicine and infrastructure investment are not specific to Infergen, but both are widening the settings where tailored antiviral care can be delivered.

What's next: - The market is expected to keep shifting toward narrower, more targeted use of Infergen rather than broad adoption. - Growth will likely depend on how quickly hepatitis C screening expands and how often clinicians need backup options for resistant patients. - The report says its 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated trend analysis.